Generics· July 2, 2026 · 18 min read
Why Generic Jardiance Has Not Launched: Empagliflozin Patent Cliff
By Ran Chen#Generic Entry#Orange Book#SGLT2 Inhibitor
Topic
SGLT2 Inhibitor
Empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, sotagliflozin — SGLT2 inhibitor access, formulary placement, IRA pricing, and generic entry.
Evidence· June 15, 2026 · 11 min read
SGLT2 inhibitors in FAERS: 154,476 adverse-event reports by the numbers
Generics· June 9, 2026 · 9 min read
Dapagliflozin generic entry: Farxiga ANDA playbook and formulary impact
By Ran Chen#SGLT2 Inhibitor#ANDA Approval#Orange Book
Pricing & Access· May 24, 2026 · 11 min read
SGLT2 inhibitor access landscape in 2026
Pricing & Access· May 18, 2026 · 11 min read
Jardiance vs Farxiga: label, access, and payer coverage compared
Pricing & Access· May 17, 2026 · 10 min read
Farxiga coverage guide: formulary, prior authorization, and what access teams should know
Pricing & Access· May 17, 2026 · 9 min read